Clinical trials
Targeted Therapy clinical trials
Below are recruiting targeted therapy clinical trials, each written for real people, not researchers. We’re tracking 309 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07575919RecruitingPhase 1/Phase 2
CAR-T Cell Therapy for Standard-Risk B-ALL After Chemotherapy
This trial tests a new type of immunotherapy called CAR-T cells to help prevent relapse in adults with B-cell acute lymphoblastic leukemia (a blood cancer) who have responded well to standard chemotherapy. The treatment is designed as a consolidation therapy to strengthen remission after initial chemotherapy.
Beijing, Beijing MunicipalityAges 18–85 - NCT06481735RecruitingPhase 1/Phase 2
Modified donor CAR-T for B-cell leukemia
This trial tests a new type of CAR-T cell therapy for people with B-cell acute lymphoblastic leukemia that has returned or not responded to standard treatment. The CAR-T cells are made from a donor and modified to target the CD19 protein on leukemia cells.
Beijing, Beijing MunicipalityAges 16–70 - NCT06014073RecruitingPhase 1/Phase 2
A new CAR-T cell therapy for relapsed B-cell lymphoma
This trial tests a special type of CAR-T cell therapy for people with B-cell lymphoma that has come back or not responded to standard treatments. The CAR-T cells are made from a donor and have genes removed to work better. The goal is to see if this treatment is safe and effective.
BeijingAges 18–70 - NCT06323525RecruitingPhase 1/Phase 2
Modified CAR-T cell therapy for relapsed/refractory B-cell lymphoma
This trial tests a new type of CAR-T cell therapy for people with certain B-cell lymphomas that have come back or not responded to treatment. The CAR-T cells are made from a donor and are genetically edited to possibly work better and last longer.
Beijing, Beijing MunicipalityAges 18–70 - NCT07575971RecruitingPhase 1/Phase 2
CAR-T Cell Therapy for High-Risk B-Cell Acute Lymphoblastic Leukemia
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target leukemia cells after chemotherapy has put your disease into remission. The goal is to help prevent the leukemia from coming back, especially for patients at high risk of relapse.
Beijing, Beijing MunicipalityAges 18–85 - NCT07293247RecruitingPhase 2
Targeted radiation after lung cancer surgery
This trial tests if targeted radiation after surgery can help people with non-small cell lung cancer who still have cancer in their lymph nodes after chemotherapy. Participants will have had surgery and chemotherapy before starting radiation.
Jonesboro, ArkansasAges 18 years+ - NCT07361094RecruitingPhase 1
CAR-T therapy for autoimmune disease after prior treatment
This trial tests a new CAR-T cell therapy that targets two proteins (CD19 and BCMA) on immune cells. It is for people with certain autoimmune diseases (like lupus or scleroderma) that have not responded well to standard treatments or have relapsed after prior cell therapy.
BeijingAges 18–70 - NCT06838832RecruitingPhase 1/Phase 2
New CAR-T cell therapy for relapsed B-cell lymphoma
This trial tests a new treatment made from your own immune cells (gamma-delta T cells) that are engineered to find and kill CD19-positive lymphoma cells. It is for people with B-cell non-Hodgkin lymphoma whose cancer has not responded to or has returned after at least two standard treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT07359014Recruiting
Dual-target car-t cell therapy for multiple myeloma
This trial tests a new type of immunotherapy using your own immune cells (called CAR-T cells) that are modified to attack two targets (CD19 and BCMA) on myeloma cells. It is for patients whose myeloma has come back or stopped responding to standard treatments.
HangzhouAges 18–75 - NCT06728189RecruitingPhase 1
CD70-targeted CAR-NKT cells for advanced solid tumors
This trial tests a new type of immune cell therapy (CAR-NKT cells) that targets a protein called CD70 on cancer cells. It is for people with advanced solid tumors that have not responded to at least two prior treatments.
BeijingAges 18–75 - NCT06394622RecruitingPhase 1
CAR-NKT cells targeting CD70 for advanced solid tumors
This trial tests a new type of immune cell therapy (CAR-NKT) that targets a protein called CD70 on cancer cells. It is for people with advanced solid tumors that have not responded to at least two prior treatments and whose tumors are CD70-positive.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT04271644RecruitingPhase 1/Phase 2
CAR-T treatment targeting BCMA for hard-to-treat myeloma
This Phase 1/2 study tests a BCMA-targeting CAR-T cell therapy for people with relapsed or refractory multiple myeloma or related plasma cell diseases. It may help by using your own immune cells, engineered to recognize a specific target on cancer cells.
Kunming, YunnanAges 18–75 - NCT04512716RecruitingEarly Phase 1
Radioimmunotherapy then CD19 CAR T for hard-to-treat blood cancers
This early-phase study tests a two-step treatment: first a targeted radioactive antibody (131-I apamistamab) and then CD19 CAR T-cell therapy. It is for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) or diffuse large B-cell lymphoma (DLBCL) that is not responding or has come back, aiming to shrink cancer using engineered immune cells.
Basking Ridge, New JerseyAges 18 years+ - NCT05003895RecruitingPhase 1
CAR-T for solid tumors with high GPC3 protein
This early-phase trial tests a personalized CAR-T cell treatment for cancers that make a lot of a protein called GPC3. If you have advanced cancer that has already tried at least one standard treatment, and your tumor has enough GPC3, this study aims to see how well the treatment can shrink tumors and how safe it is.
Bethesda, MarylandAges 18–120 - NCT05169177Recruiting
Tracking liver tumor medicine on CT during radiation
This study checks whether a special “contrast” medicine used in liver cancer can be clearly seen on CT images while you receive radiation. The goal is to better track where the medicine is during treatment, which may improve how radiation is guided.
Waratah, New South WalesAges 18 years+ - NCT05554939RecruitingPhase 1/Phase 2
CAR-T cells targeting CD19 for relapsed B-cell lymphoma
This Phase 1/2 trial studies an “off-the-shelf” (allogeneic) immune-cell therapy that targets CD19, a marker on many B-cell lymphomas. It’s for adults whose lymphoma has come back or didn’t respond to prior treatment, aiming to shrink tumors and improve outcomes.
Beijing, Beijing MunicipalityAges 18–75 - NCT06623396RecruitingPhase 1
CAR T-cell therapy for stomach and esophagus cancer
This trial tests a new treatment called CAR T-cell therapy that targets a protein called mesothelin found on some cancer cells. It is for people with advanced or recurrent cancer of the stomach or esophagus that has spread or come back after prior treatment.
Basking Ridge, New JerseyAges 18 years+ - NCT06775912RecruitingEarly Phase 1
CAR-T cell therapy for autoimmune diseases
This trial tests a new CAR-T cell therapy that targets two proteins (CD19 and BCMA) on immune cells. It's designed for people with certain autoimmune diseases like lupus, scleroderma, vasculitis, myositis, or Sjögren's syndrome that are not controlled by standard treatments.
Lianyungang, JiangusAges 18–70 - NCT07008885RecruitingPhase 1/Phase 2
New CAR-T cell therapy for relapsed/refractory B-ALL
This trial tests a new type of CAR-T cell therapy that is engineered to be more effective against a specific kind of leukemia (B-ALL) that has returned or not responded to treatment. The therapy uses a patient's own immune cells to target and destroy cancer cells.
Beijing, Biotherapeutic Department of Chinese PLA General HospitalAges 18–70 - NCT07009002RecruitingPhase 1/Phase 2
Modified CAR-T cell therapy for relapsed B-cell lymphoma
This study tests a new kind of CAR-T cell therapy for people with certain types of B-cell lymphoma that have come back or not improved after standard treatments. The CAR-T cells have been modified to turn off two genes (BCOR and ZC3H12) to make them work better against the cancer.
Beijing, Beijing MunicipalityAges 18–70 - NCT04776330RecruitingPhase 1/Phase 2
BCMA-targeted CAR-T for relapsed or refractory multiple myeloma
This trial tests a lab-made immune cell therapy (CAR-T) designed to attack a protein called BCMA on myeloma cells. It’s for adults whose multiple myeloma or related plasma cell disease has come back or didn’t respond to prior treatment, aiming to improve cancer control.
Kunming, YunnanAges 18–75 - NCT05439226Recruiting
Diet plan targeting liver fat for type 2 diabetes
This study tests whether a Chinese medical nutrition therapy diet can reduce liver fat and help manage type 2 diabetes in people who also have fatty liver. You may be asked to follow a specific eating plan and keep your diabetes care stable during the study.
Yichang, HubeiAges 18–75 - NCT05621668RecruitingPhase 1
First drug trial using engineered T-cells for sarcoma
This Phase 1 trial tests a new immune therapy made from your T-cells and engineered to target sarcoma tumors. It is designed to see if the treatment is safe and whether it can shrink advanced or metastatic soft tissue or bone sarcoma.
Houston, TexasAges 12 years+ - NCT05839379Recruiting
Targeted therapy study for children and young adults with brain tumors
This trial studies a targeted medicine approach for high-grade glioma (a fast-growing brain tumor) and some diffuse midline tumors, including DIPG. It may help by matching treatment to tumor biology using tumor testing done before or around starting standard therapy.
Aurora, ColoradoAges 1–39
Hear when a new Targeted Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for targeted therapy?
- Yes. Clin2 currently lists 309 recruiting targeted therapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a targeted therapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a targeted therapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.